DRMAW vs XYL
Dermata Therapeutics Inc. Warrant (DRMAW) versus Xylem Inc (XYL) — a side-by-side from cached financials, not a winner call.
Dermata Therapeutics Inc. Warrant (DRMAW) common stock listed on NASDAQ.
Xylem Inc (XYL) is a specialty industrial machinery company listed on NYSE.
DRMAW does not have a complete income-statement cache yet.
Latest reported XYL revenue for 2026-06-30 was $4.46B. Net income was $456.0M. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
DRMAW currently screens at market cap $0. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
Not investment advice. Open the DRMAW and XYL stock pages for the full models.
Not investment advice.